BDX Introduces BD Research Cloud 7.0 for Advanced Flow Cytometry

Core Insights - Becton, Dickinson and Company (BDX) has launched BD Research Cloud 7.0, enhancing its AI-driven life sciences strategy and flow cytometry capabilities [1][4] - The BD Horizon Panel Maker is a key feature of the release, aimed at optimizing experimental panel design in immunology and cancer research [2][8] Company Developments - The launch of BD Research Cloud 7.0 is expected to deepen customer lock-in, increase utilization of flow cytometry instruments, and expand recurring revenue from software and consumables [4] - BDX's market capitalization stands at $57.49 billion [5] Stock Performance - Following the announcement, BDX shares remained flat, with a 6-month gain of 11.2%, compared to an 11.5% decline in the industry and a 10.8% gain in the S&P 500 [3] Product Features - BD Research Cloud 7.0 offers a cloud-based ecosystem for flow cytometry, improving collaboration and laboratory operations [7] - The BD Horizon Panel Maker utilizes AI to generate optimized panel recommendations quickly, reducing the risk of poorly designed panels [8][9] Industry Outlook - The global flow cytometry market is projected to grow from $4.68 billion in 2024 to $7.01 billion by 2030, with a CAGR of 8.41% from 2025 to 2030, driven by rising incidences of cancer and other diseases [10]